Intimation under Regulation 30 - Rs. 517 Crores Global Sourcing Mandate
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has secured a ₹517 crore global sourcing mandate from Fortune Sagar Impex Company Limited, Thailand. The mandate is fee-based — the company will earn a fixed 5% commission on the cost of goods sourced, translating into an estimated service income of about ₹25.85 crore to be recognised in FY 2025-26. Under the Ex-Works model, Welcure handles only sourcing and procurement of finished-dosage pharmaceutical SKUs, while the buyer is responsible for packaging, labelling, freight, insurance, and regulatory clearances in the destination country. Goods will be delivered in call-off tranches, with the first lot mobilised after prefunding milestones and the balance expected by 30 September 2026. The filing confirms this is not a related-party transaction.
This adds a meaningful chunk of fee-based revenue without putting extra burden on Welcure's balance sheet, but actual income recognition is thin (~5% margin) and contingent on call-offs being activated by the Thai client over the next ~15 months.